Related Experiment Video
Updated: May 5, 2026

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
Published on: July 3, 2013
Clinical use of calcium channel blockers as ventricular unloading agents
Insights
Nifedipine effectively treated hypertensive heart failure by reducing blood pressure and improving cardiac function, unlike verapamil which showed limited benefits and potential side effects.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Calcium channel blockers are used to manage hypertension and heart failure.
- Hypertensive patients with cardiac enlargement present unique challenges for treatment.
Purpose of the Study:
- To compare the efficacy of nifedipine and verapamil in hypertensive patients with cardiac enlargement and heart failure symptoms.
- To evaluate the acute and chronic effects of these drugs on hemodynamic parameters and cardiac function.
Main Methods:
- A comparative study involving 23 hypertensive patients with cardiac enlargement.
- Patients received either nifedipine or verapamil in acute and 1-month therapeutic evaluations.
- Hemodynamic parameters, including systemic vascular resistance (SVR), mean arterial pressure (MAP), pulmonary wedge pressure (PWP), left ventricular diastolic diameter (LV DD), cardiac index (CI), and Vcf, were measured.
Main Results:
- Nifedipine significantly reduced SVR, MAP, PWP, and LV DD, while improving CI and Vcf, with relief of dyspnea and lung congestion.
- Verapamil reduced SVR and MAP, improved CI, but did not significantly affect PWP, LV DD, or Vcf. Two patients discontinued verapamil due to severe dyspnea.
- Nifedipine demonstrated superior efficacy in improving cardiac function and relieving heart failure symptoms compared to verapamil.
Conclusions:
- Nifedipine is a more effective ventricular unloading agent than verapamil in hypertensive patients with cardiac enlargement and heart failure.
- The differing effects may be due to verapamil's less potent vasodilation and greater depression of cardiac contractility.
- Nifedipine offers a favorable therapeutic option for managing functional changes in the failing hypertensive heart.
Abstract:
Calcium channel blockers relax the arterial smooth vasculature and lower blood pressure when it is elevated because of excessive vasoconstriction. They may be regarded as ventricular unloading agents. Nifedipine (11 cases, Group 1) and verapamil (12 cases, Group 2) were tested in hypertensive patients with cardiac enlargement (LV diastolic diameter greater than or equal to 60 mm), ECG signs of LV strain, lung congestion and dyspnea at rest, in an acute (nifedipine 20 mg; verapamil 160 mg) and 1-month (nifedipine 20 mg q.i.d.; verapamil 160 mg t.i.d.) therapeutic evaluation. In the acute study nifedipine reduced systemic vascular resistance (SVR), mean arterial pressure (MAP), mean pulmonary wedge pressure (PWP) and LV diastolic diameter (DD) and improved cardiac index (CI) and Vcf. In Group 2 verapamil reduced SVR and MAP, improved CI and was not effective on PWP, LV DD and Vcf. Verapamil was discontinued in 2 patients who developed severe dyspnea at rest after 3-4 days of continued oral treatment. At the end of the trial Vcf, PWP and LV DD were unchanged in the remaining subjects in Group 2 despite persistent pressure reduction. In Group 1 all of the patients had relief of dyspnea and lung congestion, reduction of heart size, persistent decrease of MAP and PWP, and improvement in Vcf. The only side effect was ankle edema in 4 cases. A less potent vasodilating action of verapamil and a predominant depression in cardiac contractility may account for the different results with the two drugs, in spite of a shared antihypertensive effect. These findings prove that functional changes in the failing hypertensive heart may differ after nifedipine compared to verapamil as a result of interaction and relative preponderance of influences on afterload and contractility.
More Related Videos
08:25Voltage and Calcium Dual Channel Optical Mapping of Cultured HL-1 Atrial Myocyte Monolayer
Published on: March 23, 2015
11:00Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
Published on: September 18, 2017
Related Concept Videos
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: β-Blockers
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...